

ECHO IQ LAUNCHES ECHOSOLV™ FOR IMMEDIATE DISTRIBUTION TO US HEALTHCARE MARKET

Highlights:

- Echo IQ launches EchoSolv™ to the US cardiology sector
- Echo IQ's first SaaS platform available for immediate commercial distribution to registered healthcare customers
- EchoSolv™ designed to support faster, more accurate detection of aortic stenosis
- Product designed to operate with consistency, free from bias of patient gender, age and background

Sydney: AI and Medical Technology company Echo IQ ("the Company") (ASX:EIQ) is pleased to announce that its cloud-based enhanced screening platform for structural heart disease, commencing with aortic stenosis, is now available to registered customers in the US. The platform will be sold under the name EchoSolv™ which has been chosen to reflect the importance of identifying patients at risk of structural heart disease, and the vital role that analysis of echocardiograms plays in meeting that challenge.

The EchoSolv™ software platform is designed to support clinicians and physicians in identifying patients with guideline-defined aortic stenosis in the first instance. Whilst treatment options for sufferers of severe aortic stenosis are considered safe and reliable, the condition has a 2-year mortality rate of 50% when left untreated. EchoSolv™ is designed to ensure patients who would benefit from treatment or further clinical review are accurately identified.

The rigorously tested product has been developed in consultation with leading cardiologists. Echo IQ's Chief Medical Advisor and Cardiologist, Professor David Playford indicates that EchoSolv™ "automates the identification of high-risk aortic stenosis patients. It heralds the beginning of a new era by improving the cardiologist's focus on patients at-risk without requiring any change of cardiac imaging solution, no new hardware, no new devices, and no new interference with existing infrastructure."


Key Product Features

- Rapid automated assessment of echocardiographic measurements for consistent analysis
- Bulk assessments completed at a rate of up to 48,000 per minute
- EchoSolv™ dashboard displays whether in-guideline thresholds have been met plus displays of key measurements and time-stamped assessments
- Optional SMS/Email alerts for high-risk patients
- Results can be exported in PDF and other formats
- Ability to deploy platform to new markets incorporating local regulatory frameworks
- Available Web Application Programming Interface (API) supports optional integration into existing workflows/systems for real-time results

- Role based access controls for audit and usage traceability
- Cloud-based HIPAA and SOC2 compliant platform ensures security of patient and provider information

Echo IQ is initially introducing EchoSolv™ in the United States where the Company has recently achieved positive results with the product in a clinical efficacy study with Harvard Medical School's Beth Israel Deaconess Medical Center. This study demonstrated that EchoSolv™ successfully identified sizeable cohorts of patients with guideline-detected severe aortic stenosis as well those with a significantly heightened risk of death from the condition.

Echo IQ is launching EchoSolv™ with two pricing models. A price-per-assessment model will see customers conducting retrospective reviews charged for any records evaluated. For those customers integrating EchoSolv™ into real-time clinical workflows for immediate patient assessments, a flat monthly SaaS fee will be charged.



(Figure 1: EchoSolv™)

US healthcare professionals in echocardiology clinics, hospitals and health systems as well as ambulatory surgery centres (ASCs) are invited to contact Echo IQ (<https://www.echoiq.ai/contact-us/>) for a demonstration and information on how EchoSolv™ can add value to their clinical practice.

Comments

Echo IQ Chief Commercial Officer Deon Strydom said: “The launch of EchoSolv™ gives healthcare professionals a powerful new decision-support tool to help identify patients who might benefit from proven therapies for severe aortic stenosis. Whether used retrospectively to assess existing records or integrated into real-time clinical workflows, clinicians now have access to an additional layer of assessment in support of more effective patient care.

We are pleased to be taking this important step in the US where a number of significant milestones have been met. Our experienced and highly regarded healthcare executive Don Fowler is already engaging with several leading hospitals, ASCs and health systems in leading US cardiology markets from his base in Austin, TX and we expect to be seeing EchoSolv™ deployed with a number of these at pace. Looking further ahead, we look forward to incorporating new features, capabilities, and additional conditions beyond aortic stenosis into EchoSolv™ – many of which are currently in development.”

Echo IQ Chief Technology Officer Seán Bryceland said: “EchoSolv™ brings our significant investment in research and development to market in an easy-to-deploy and user-friendly new solution that is highly secure from both systems and data perspectives. Moreover, we have worked closely with healthcare partners to incorporate features into the product that support them in the important work they do, and in a way that integrates simply into existing clinical workflows.

We know that information security is of utmost value to our partners in healthcare and the HIPAA and SOC2 compliance of our platform are but two of the many measures in place to protect information. EchoSolv™ gives users the flexibility to review echocardiographic measurements straight away or to integrate results into clinical workflows via a secure web API.”

-ENDS-

Authorised for release by the Board of Directors of Echo IQ Limited.

Media Enquiries:

Philip Woolff, Chief Operating Officer
philip.woolff@echoiq.ai / marketing@echoiq.ai / +61 (0)490 030 620

Investor Enquiries:

Andrew Grover, Executive Chair
Andrew.grover@echoiq.ai / investor@echoiq.ai

ABOUT ECHO IQ

Echo IQ uses AI-driven technology and proprietary software to improve decision making in Cardiology.
The company is based in Sydney, Australia.